TransTech reports Phase II diabetes data for GKA compound

TransTech Pharma Inc. (High Point, N.C.) said TTP399 significantly reduced HbA1c from baseline at week six vs. placebo in a Phase IIa trial to treat Type II diabetes (p<0.001). Former partner Forest Laboratories Inc. (NYSE:FRX) conducted the trial, which enrolled 128 Type II diabetics on stable doses of metformin. TransTech said it plans to start a Phase IIb trial to evaluate TTP399 for Type II diabetics late this year or in early 2014. TTP399 is a glucokinase activator (GKA). ...